Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990), or Kelun-Biotech, reacquired a negotiable certificate of deposit from Tongwei (SHA:600438) for 53 million yuan, according to a Thursday filing with the Hong Kong bourse.
The large-denomination certificate of deposit had a principal amount of 50 million yuan and was first issued to Kelun-Biotech by Industrial Bank (SHA:601166) in May 2024. It was then sold to Tongwei in March by the company, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.